Volume 18, Number 4—April 2012
Dispatch
Human Parvovirus 4 Infection, Cameroon
Table 2
Participant characteristic | All participants |
After exclusions* |
|||
---|---|---|---|---|---|
Adjusted odds ratio (95% CI) | p value | Adjusted odds ratio (95% CI) | p value | ||
Age group, y | |||||
60–64 | 2.21 (1.13–4.31) | 0.02 | 2.88 (1.16–7.17) | 0.02 | |
65–69 | 1.01 (0.46–2.24) | 0.98 | 1.20 (0.39–3.70) | 0.76 | |
70–74 | 1.16 (0.54–2.46) | 0.71 | 1.51 (0.55–4.16) | 0.42 | |
>75 | 1.00 | 1.00 | |||
Tuberculosis | |||||
No | 1.00 | 1.00 | |||
Yes, treated with oral drugs only | 2.09 (0.58–7.54) | 0.26 | 2.91 (0.63–13.51) | 0.17 | |
Yes, treatment included streptomycin | 5.21 (0.99–27.37) | 0.05 | 20.96 (1.67–262.99) | 0.02 | |
Vaccine scar, left arm | |||||
Absent | 1.00 | 1.00 | |||
Present | 0.37 (0.19–0.71) | 0.003 | 0.32 (0.13–0.78) | 0.01 | |
Intravenous treatment for malaria | 0.06 | ||||
No | 1.00 | 1.00 | |||
Yes | 1.92 (1.13–3.24) | 0.015 | 1.98 (0.97–4.03) | 0.06 |
*After exclusion of 81 participants with borderline negative results and 35 with borderline positive results.
Page created: March 15, 2012
Page updated: March 15, 2012
Page reviewed: March 15, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.